Spotlight on JLABS

Add this event to your calendar:
22/09/2016 13:30 22/09/2016 15:00 America/Los_Angeles Spotlight on JLABS JLABS , 3210 Merryfield Row , San Diego , California JLABS San Diego together with Janssen R&D false DD/MM/YYYY
September
22
Event

Spotlight on JLABS

JLABS , 3210 Merryfield Row , San Diego , California

September 22, 2016 from 13:30 PM to 15:00 PM (PST)

$10 - $35


Come one, come all! You are invited to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in San Diego. JLABS' flagship location currently holds over 40 companies and has several more in the pipeline. Four companies will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS. Don't miss this opportunity to learn more about the progress of this exciting project and meet the companies within JLABS. Please note that the presentations at this event will include publicly available, non-confidential information only.

Date:
Thursday, September 22, 2016

Agenda:
11:30am | Lunch
12:00pm | Presentations
1:00pm | Program Close

Presenting Companies:
Capella Therapeutics read more»
IDEAYA Biosciences read more»
Jecure Therapeutics read more»
Oncternal Therapeutics read more»

RSVP:
Please RSVP online so that we can get an accurate headcount for food and beverages. We will not be accepting walk-ups once the event is sold out.

Venue:
JLABS
3210 Merryfield Row
San Diego, CA

Presenting Companies' Descriptions:

Capella Therapeutics
Capella Therapeutics has discovered orally available small molecules which rapidly eliminate brain mets in mice ,in addition to obliterating extracranial drug-resistant lung cancer. These EGFR TKIs, in addition to downregulating PDL1, have other tumor microenvironment effects thru BTK/ITK and PI3K-delta. These effects include a decrease in myeloid suppressor cells and B-suppressor cells; mediation of a Th2 block involved in tumor evasion, with Th1 generation for anti-tumor activity. There is also anti-angiogenic activity. Clinicians see these features as offering an important additional efficacy in addition to the brain penetration.
Web: ideayabio.com

IDEAYA Biosciences
IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.
Web: ideayabio.com

Jecure Therapeutics
Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of fatty liver disease, NASH, and fibrosis. Our scientific founder is Dr. Ariel Feldstein, Division Chief of Gastroenterology at UCSD School of Medicine and a leading physician scientist in hepatology. Jecure Therapeutics combines cutting-edge academic biology with deeply experienced pharma/biotech scientists who are dedicated to discovering novel and impactful therapeutics for the treatment of liver disease.

Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class therapies for both rare and common malignancies. The company is leveraging its scientific and development expertise, as well as academic collaborations, to rapidly advance its two pipeline products focused on embryonic targets that are aberrantly expressed by cancer cells. Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody, currently in a phase 1 clinical trial for CLL, which identifies cancer stem cells in a number of hematologic malignancies and solid tumors. TK216 is a first-in-class small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins in a variety of tumor types that is in Phase 1 clinical testing for Ewing sarcoma. The company’s strategy is to identify orphan cancer indications with high unmet medical need and execute a fast to market registration strategy. In parallel, the company is identifying large market cancer indications with unmet medical need for the same product candidates.
Web: oncternal.com


JLABS San Diego together with Janssen R&D

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content